Literature DB >> 28597253

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial.

C Riese1, B Weiß2,3, U Borges4, A Beylich5, R Dengler6, K Hermes-Moll4, M Welslau7, W Baumann4.   

Abstract

PURPOSE: Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, oral cancer medications are difficult to handle and have a considerable potential for side effects. This type of therapy requires a high level of self-management competence by the patient. A standardized patient education program provided by physicians and oncology nurses may positively influence the handling of oral agents. The aim of the study was to evaluate the impact of a standardized patient education program provided by specially trained oncology nurses on therapy management regarding side effects and unplanned therapy interruptions.
METHODS: One hundred sixty-five patients from 28 office-based oncology practices from all over Germany participated in this cluster-randomized controlled study. Patients of both intervention (n = 111) and standard care groups (n = 54) received the usual oncologist counseling; in addition, the patients from the intervention group (k = 17 practices) received an education from specially trained oncology nurses. The time of observation was 3 months per patient.
RESULTS: The patients of the intervention group reported fewer side effects (skin rash, pain, fatigue, nausea, vomiting). Patients in the standard care group interrupted the therapy more frequently without informing their oncologist, compared to the intervention group.
CONCLUSIONS: Patients benefit from a standardized patient education program provided by specially trained oncology nurses. They tend to handle side effects and critical situations better.

Entities:  

Keywords:  Oncology nurses; Oral cancer therapy; Patient education; Therapy-related side effects; Unplanned therapy interruption

Mesh:

Year:  2017        PMID: 28597253     DOI: 10.1007/s00520-017-3770-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  24 in total

1.  Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

Authors:  C M T Schilder; C Seynaeve; S C Linn; W Boogerd; L V A M Beex; C M Gundy; J W R Nortier; C J H van de Velde; F S A M van Dam; S B Schagen
Journal:  Crit Rev Oncol Hematol       Date:  2009-12-24       Impact factor: 6.312

Review 2.  A review on adherence management in patients on oral cancer therapies.

Authors:  Leslie Wood
Journal:  Eur J Oncol Nurs       Date:  2011-11-02       Impact factor: 2.398

Review 3.  Anticancer oral therapy: emerging related issues.

Authors:  Giuseppe Luigi Banna; Elena Collovà; Vittorio Gebbia; Helga Lipari; Pietro Giuffrida; Sebastiano Cavallaro; Rosaria Condorelli; Calogero Buscarino; Paolo Tralongo; Francesco Ferraù
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

4.  A specialized home care intervention improves survival among older post-surgical cancer patients.

Authors:  R McCorkle; N E Strumpf; I F Nuamah; D C Adler; M E Cooley; C Jepson; E J Lusk; M Torosian
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

5.  Development of the MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer.

Authors:  Sultan Kav; Lisa Schulmeister; Anita Nirenberg; Linda Barber; Judi Johnson; Cynthia Rittenberg
Journal:  Support Care Cancer       Date:  2009-07-10       Impact factor: 3.603

Review 6.  Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.

Authors:  Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse
Journal:  Support Care Cancer       Date:  2014-01-26       Impact factor: 3.603

7.  Improving the Safety of Oral Chemotherapy at an Academic Medical Center.

Authors:  Nirav N Shah; Erica Casella; Donna Capozzi; Suzanne McGettigan; Tara C Gangadhar; Lynn Schuchter; Jennifer S Myers
Journal:  J Oncol Pract       Date:  2016-01-05       Impact factor: 3.840

Review 8.  The vital role of education and information in patients receiving capecitabine (Xeloda).

Authors:  Ian Chau; Sally Legge; Pierre Fumoleau
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

Review 9.  Safe administration of oral chemotherapy.

Authors:  Ann Birner
Journal:  Clin J Oncol Nurs       Date:  2003 Mar-Apr       Impact factor: 1.027

10.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

View more
  4 in total

1.  Potential negative impact of informing patients about medication side effects: a systematic review.

Authors:  Jimmy Jose; Lamia AlHajri
Journal:  Int J Clin Pharm       Date:  2018-08-23

2.  New Oral Anti-Cancer Drugs and Medication Safety.

Authors:  Katja Schlichtig; Pauline Dürr; Frank Dörje; Martin F Fromm
Journal:  Dtsch Arztebl Int       Date:  2019-11-15       Impact factor: 5.594

3.  Understanding patient engagement in health system decision-making: a co-designed scoping review.

Authors:  Tamara L McCarron; Karen Moffat; Gloria Wilkinson; Sandra Zelinsky; Jamie M Boyd; Deborah White; Derek Hassay; Diane L Lorenzetti; Nancy J Marlett; Thomas Noseworthy
Journal:  Syst Rev       Date:  2019-04-18

4.  An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum.

Authors:  Katharina Habler; Michael Vogeser; Daniel Teupser
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.